The Value of Urinary Exosomal LncRNA SNHG16 As a Diagnostic Biomarker for Bladder Cancer

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2023 Aug 17

PMID 37592177

Authors

Chengyi Liu

Pengcheng Xu

Song Shao

Fang Wang

Zhiwen Zheng

Shuangjie Li

Wei Liu

Guangyuan Li

Affiliations

Soon will be listed here.

Abstract

Objective: To detect the expression level of urinary exosomal lncRNA SNHG16 in patients with bladder cancer and healthy individuals and explore its clinical application value in the diagnosis of bladder cancer.

Methods: Urine samples were collected from 42 patients with bladder cancer and 42 healthy volunteers who visited Lu'an Hospital of Anhui Medical University and the Second Hospital of Tianjin Medical University from January 2020 to December 2022. The expression levels of lncRNA SNHG16 in urinary exosomes of the two groups were detected by RT‒qPCR, and their correlation with clinical pathological parameters of bladder cancer patients was analysed. An Receiver Operating Characteristic(ROC) curve was drawn to analyse the diagnostic value of urinary exosomal lncRNA SNHG16 for bladder cancer and compared with urinary cytology.

Results: The expression of urinary exosomal lncRNA SNHG16 in patients with bladder cancer was significantly higher (P < 0.05), and the expression level had no correlation with the age, sex, pathological T stage, pathological grade, or tumour size of bladder cancer patients (P > 0.05). The Area Under Curve(AUC) of urinary exosomal lncRNA SNHG16 in diagnosing bladder cancer was 0.791, which was superior to that of urinary cytology (AUC = 0.597).

Conclusion: Urinary exosomal lncRNA SNHG16 with high expression can serve as a potential diagnostic biological marker for bladder cancer.

Citing Articles

Recent Exploration of Solid Cancer Biomarkers Hidden Within Urine or Blood Exosomes That Provide Fundamental Information for Future Cancer Diagnostics.

Hara T, Meng S, Alshammari A, Hatakeyama H, Arao Y, Saito Y Diagnostics (Basel). 2025; 15(5).

PMID: 40075875 PMC: 11899240. DOI: 10.3390/diagnostics15050628.

Epigenetic Biomarkers as a New Diagnostic Tool in Bladder Cancer-From Early Detection to Prognosis.

Jaszek N, Bogdanowicz A, Siwiec J, Starownik R, Kwasniewski W, Mlak R J Clin Med. 2024; 13(23).

PMID: 39685620 PMC: 11642161. DOI: 10.3390/jcm13237159.

Extracellular Vesicle lncRNAs as Key Biomolecules for Cell-to-Cell Communication and Circulating Cancer Biomarkers.

Papoutsoglou P, Morillon A Noncoding RNA. 2024; 10(6).

PMID: 39585046 PMC: 11587107. DOI: 10.3390/ncrna10060054.

The diagnostic accuracy of urine-derived exosomes for bladder cancer: a systematic review and meta-analysis.

Long C, Shi H, Li J, Chen L, Lv M, Tai W World J Surg Oncol. 2024; 22(1):285.

PMID: 39472962 PMC: 11520875. DOI: 10.1186/s12957-024-03569-1.

LncRNA SNHG16 Inhibits Intracellular Growth Involving Cathelicidin Pathway, Autophagy, and Effector Cytokines Production.

Huang G, Wu X, Ji X, Peng Y, Wang J, Cai X ACS Omega. 2024; 9(42):43115-43128.

PMID: 39464459 PMC: 11500371. DOI: 10.1021/acsomega.4c07053.

References

Zippe C, Pandrangi L, Potts J, Kursh E, Novick A, Agarwal A . NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer. Anticancer Res. 1999; 19(4A):2621-3. View

Grossman H . New methods for detection of bladder cancer. Semin Urol Oncol. 1998; 16(1):17-22. View

Ding X, Zhang S, Deng X, Qiang J . Serum Exosomal lncRNA DLX6-AS1 Is a Promising Biomarker for Prognosis Prediction of Cervical Cancer. Technol Cancer Res Treat. 2021; 20:1533033821990060. PMC: 7876577. DOI: 10.1177/1533033821990060. View

Yang H, Fu H, Xu W, Zhang X . Exosomal non-coding RNAs: a promising cancer biomarker. Clin Chem Lab Med. 2016; 54(12):1871-1879. DOI: 10.1515/cclm-2016-0029. View

Abbastabar M, Sarfi M, Golestani A, Karimi A, Pourmand G, Khalili E . Tumor-derived urinary exosomal long non-coding RNAs as diagnostic biomarkers for bladder cancer. EXCLI J. 2020; 19:301-310. PMC: 7104196. DOI: 10.17179/excli2019-1683. View

Li G, Zhang Y, Mao J, Hu P, Chen Q, Ding W . lncRNA TUC338 is a potential diagnostic biomarker for bladder cancer. J Cell Biochem. 2019; 120(10):18014-18019. DOI: 10.1002/jcb.29104. View

Pode D, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I . Noninvasive detection of bladder cancer with the BTA stat test. J Urol. 1999; 161(2):443-6. View

Feng F, Chen A, Huang J, Xia Q, Chen Y, Jin X . Long noncoding RNA SNHG16 contributes to the development of bladder cancer via regulating miR-98/STAT3/Wnt/β-catenin pathway axis. J Cell Biochem. 2018; 119(11):9408-9418. DOI: 10.1002/jcb.27257. View

Ramakumar S, Bhuiyan J, Besse J, Roberts S, Wollan P, Blute M . Comparison of screening methods in the detection of bladder cancer. J Urol. 1999; 161(2):388-94. View

10.

Aggen D, Drake C . Biomarkers for immunotherapy in bladder cancer: a moving target. J Immunother Cancer. 2017; 5(1):94. PMC: 5697433. DOI: 10.1186/s40425-017-0299-1. View

11.

Cai C, Zhang H, Zhu Y, Zheng P, Xu Y, Sun J . Serum Exosomal Long Noncoding RNA pcsk2-2:1 As A Potential Novel Diagnostic Biomarker For Gastric Cancer. Onco Targets Ther. 2019; 12:10035-10041. PMC: 6883939. DOI: 10.2147/OTT.S229033. View

12.

Dai G, Huang C, Yang J, Jin L, Fu K, Yuan F . LncRNA SNHG3 promotes bladder cancer proliferation and metastasis through miR-515-5p/GINS2 axis. J Cell Mol Med. 2020; 24(16):9231-9243. PMC: 7417716. DOI: 10.1111/jcmm.15564. View

13.

Crozier J, Papa N, Perera M, Ngo B, Bolton D, Sengupta S . Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta-analysis. World J Urol. 2018; 37(4):667-690. DOI: 10.1007/s00345-018-2439-8. View

14.

Zhang D, Du D, Yi S, Li X . LncRNA PCAT6: A potential biomarker for diagnosis and prognosis of bladder cancer. Ann Diagn Pathol. 2020; 49:151642. DOI: 10.1016/j.anndiagpath.2020.151642. View

15.

Ke D, Wang Q, Ke S, Zou L, Wang Q . Long-Non Coding RNA SNHG16 Supports Colon Cancer Cell Growth by Modulating miR-302a-3p/AKT Axis. Pathol Oncol Res. 2019; 26(3):1605-1613. DOI: 10.1007/s12253-019-00743-9. View

16.

Santangelo L, Giurato G, Cicchini C, Montaldo C, Mancone C, Tarallo R . The RNA-Binding Protein SYNCRIP Is a Component of the Hepatocyte Exosomal Machinery Controlling MicroRNA Sorting. Cell Rep. 2016; 17(3):799-808. DOI: 10.1016/j.celrep.2016.09.031. View

17.

Rui X, Wang L, Pan H, Gu T, Shao S, Leng J . LncRNA GAS6-AS2 promotes bladder cancer proliferation and metastasis via GAS6-AS2/miR-298/CDK9 axis. J Cell Mol Med. 2018; 23(2):865-876. PMC: 6349183. DOI: 10.1111/jcmm.13986. View

18.

Tao Y, Tang Y, Yang Z, Wu F, Wang L, Yang L . Exploration of Serum Exosomal LncRNA TBILA and AGAP2-AS1 as Promising Biomarkers for Diagnosis of Non-Small Cell Lung Cancer. Int J Biol Sci. 2020; 16(3):471-482. PMC: 6990900. DOI: 10.7150/ijbs.39123. View

19.

Zhang S, Du L, Wang L, Jiang X, Zhan Y, Li J . Evaluation of serum exosomal LncRNA-based biomarker panel for diagnosis and recurrence prediction of bladder cancer. J Cell Mol Med. 2018; 23(2):1396-1405. PMC: 6349164. DOI: 10.1111/jcmm.14042. View

20.

Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat E . EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2016; 71(3):447-461. DOI: 10.1016/j.eururo.2016.05.041. View